• DZNep: Mechanism, Scope, and Evidence Boundaries

  2026-10-14

  3-Deazaneplanocin A hydrochloride, or DZNep, is described by APExBIO as an epigenetic research compound associated with EZH2/PRC2 depletion, reduced H3K27me3, and inhibition of S-adenosylhomocysteine hydrolase. The supplied product information also reports effects in AML cell lines and a diet-induced NAFLD rat model, but provides no matched paper, numerical effect sizes, sample sizes, or independent evidence sufficient to establish causality, selectivity, or general applicability.

• Selonsertib and ASK1 Signaling in Lupus Nephritis

  2026-10-14

  A source-grounded editorial assessment of Selonsertib (GS-4997) as a preclinical ASK1-pathway probe in lupus nephritis, emphasizing reported findings, mechanistic interpretation, and limits on translation.

• QPRT, P2Y11 Signaling, and Breast Cancer Invasion

  2026-10-13

  A source-grounded overview of how Liu et al. linked QPRT expression with breast cancer invasiveness, myosin light-chain phosphorylation, and P2Y11-associated signaling, while noting the study’s preclinical scope and evidentiary limits.

• Entecavir (BMS200475): Evidence and Limits

  2026-10-13

  Entecavir has a documented role as an HBV polymerase inhibitor, but the supplied evidence combines commercial product claims with a single case report. The case report supports a possible rare association with severe thrombocytopenia, while its design cannot establish incidence, comparative risk, or broad clinical applicability.

• ATRX Loss and Drug Sensitivity in High-Grade Glioma

  2026-10-12

  A 2022 cell-based study reported greater sensitivity of ATRX-deficient high-grade glioma models to several receptor tyrosine kinase and PDGFR inhibitors, including stronger toxicity in some combinations with temozolomide. The findings are hypothesis-generating rather than evidence of clinical efficacy, and their applicability is limited by the preclinical models, drug heterogeneity, and potential genomic confounding.

• Macrocyclic Inhibitors Target TMPRSS2

  2026-10-12

  Tombling et al. report highly selective macrocyclic peptide inhibitors of TMPRSS2, including T2-MCP-19, and show that binding affinity, proteolytic stability, and cellular context must be evaluated together. The evidence is preclinical and primarily in vitro.

• Isochlorogenic Acid A: Evidence and Boundaries

  2026-10-11

  Isochlorogenic acid A, also known as 3,5-Dicaffeoylquinic acid, is a caffeoylquinic acid natural product being investigated in formulation-focused wound-repair research. A 2026 preclinical study reported antibacterial, material, cell-migration, inflammatory-marker, and wound-closure findings for an IAA/Fe(III)-loaded hydrogel, but the evidence remains formulation-specific and does not establish clinical efficacy or a compound-specific mechanism.

• WDR36, Glycolysis, and Embryo State

  2026-10-10

  The WDR36 study reframes early human lineage commitment as a metabolism-linked regulatory problem. This analysis examines what the evidence establishes, where the blastoid model is informative, how cytokine tools such as Recombinant Human IL-6, Tag Free may fit carefully bounded translational studies, and why mechanistic restraint matters.

• RIN3–BIN1 Binding and Endosomal Pathology in AD

  2026-10-09

  A 2026 Science Advances study links impaired RIN3–BIN1 binding to RAB5 hyperactivation, enlarged neuronal endosomes, and Alzheimer’s disease–relevant transcriptional changes. By combining mouse genetics with edited human iPSC-derived neurons, the work strengthens the case that BIN1 regulates RIN3-dependent endosomal homeostasis, while also defining important limits for therapeutic interpretation.

• SB 431542: Reframing ALK5 Research for Translation

  2026-10-09

  SB 431542 is more than a pathway inhibitor: it is a mechanistic probe for separating ALK5-dependent TGF-β biology from broader receptor-family and inflammatory effects. This article examines how its reported selectivity, Smad2-centered pharmacology, glioma findings, and immunology applications can be interpreted alongside new evidence on PHF2-driven neuroinflammation—while defining the limits of current translational evidence.

• 4-Phenylbutyric Acid in ER Stress Research

  2026-10-08

  A source-grounded overview of 4-Phenylbutyric acid and 4-PBA as research tools for interpreting ER stress, autophagy, and cell-death mechanisms, with emphasis on published findings, evidence strength, provenance, and applicability limits.

• Super-Enhancer Hijacking in Early Lung Adenocarcinoma

  2026-10-08

  Zhang et al. identify LINC01977 as a super-enhancer-associated long noncoding RNA that links tumor-associated macrophage signaling to the canonical TGF-β/SMAD3 pathway in early-stage lung adenocarcinoma. The study provides a mechanistic framework for understanding how enhancer dysregulation, transcriptional coactivator recruitment, and tumor microenvironment signals may jointly promote relapse-associated biology.

• Prednisolone and ERAD: Evidence and Research Context

  2026-10-07

  Prednisolone is a synthetic glucocorticoid used to study glucocorticoid receptor signaling, inflammation modulation, and immune-cell responses. A 2026 Cell study describes a distinct targeted protein degradation platform based on desonide-derived ERAD-engaging chimeras; current evidence does not establish Prednisolone as an ERAD warhead or connect it directly to PD-L1 or mutant HTT degradation.

• NF 340: Interpreting P2Y11 Evidence

  2026-10-07

  Explore how the P2Y11 antagonist NF 340 helps interpret the connection between QPRT, purinergic signaling, and breast cancer cell invasiveness. This evidence-focused guide separates reported findings from mechanistic inference and outlines broader implications for immunology research and inflammation pathway modulation.

• Dorsomorphin (Compound C): Evidence and Limits

  2026-10-06

  Dorsomorphin, also called Compound C, is a reversible ATP-competitive AMPK inhibitor with additional BMP-pathway activity. Its dual pharmacology makes it useful for mechanistic research, but cellular findings require careful separation of AMPK-dependent, BMP-dependent, and broader stress-response effects.

8463 records 1/565 page Next 12345 下5页 Last page